Evre IV Epitelyal Over Kanseri Olan Hastada Sitoredüktif Cerrahi ve Sisplatin ile HİPEK Sonrası Kronik Böbrek Yetmezliği: Olgu Sunumu

Abstract

İleri evre over kanseri tedavisinde maksimal sitoredüksiyon sonrası platin bazlı kemoterapi yaygın olarak kullanılan standart tedavi yaklaşımıdır. Son yıllarda ileri evre epitelyal over kanseri (EOK) için hipertermik intraperitoneal kemoterapi (HİPEK) uygulanasıda sık kullanılmaya başlanmıştır. Yakın tarihli yapılan bir çalışmada TSR'yi takip eden HİPEK'in evre III EOK'li hastalarda genel sağkalımı artırdığı gösterilmesine rağmen HİPEK komplikasyonları iyi çalışılmamıştır. Bu çalışmada, neoadjuvan kemoterapi ve ardından TSR’yi takiben sisplatin ile HİPEK alan 45 yaşında ileri evre EOK tanılı hastada gelişen postoperatif kronik böbrek yetmezliği sunulmuştur

Keywords

• Yumurtalık kanseri
• sitoredüksiyon
• HİPEK
• sisplatin
• akut böbrek hasarı
• kronik böbrek yetmezliği
• hemodiyaliz

Chronic Kidney Failure in a Patient with Stage IV Epithelial Ovarian Cancer After Cytoreductive Surgery Following HIPEC with Cisplatin: A Case Report

Abstract

The mainstay of treatment for advanced-stage ovarian cancer is a maximal surgical effort for complete cytoreduction (CRS) defined as no visible residual disease followed by platinum-based adjuvant chemotherapy. Hyperthermic intraperitoneal chemotherapy (HIPEC) has been started to use for advanced-stage epithelial ovarian cancer (EOC). Although a recent study showed that HIPEC following interval CRS improves the overall survival in patients with stage III EOC, its complications are not well studied. This report aims to present a 45-year-old female with advanced-stage EOC who had neoadjuvant chemotherapy, followed by CRS and HIPEC with cisplatin. Postoperatively, she developed acute kidney injury that was found to be due to HIPEC with cisplatin and complicated by chronic renal failure requiring lifelong hemodialysis.

Keywords

• ovarian cancer
• cytoreductive surgery
• HIPEC
• cisplatin
• acute kidney injury
• chronic kidney failure
• hemodialysis

References

1. 1. Siegel, R.L., K.D. Miller, and A. Jemal, Cancer statistics, 2018. CA Cancer J Clin, 2018. 68(1): p. 7-30.
2. 2. van Driel, W.J., et al., Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer. N Engl J Med, 2018. 378(3): p. 230-240.
3. 3. Dagel, T., et al., Hyperthermic intraperitonal chemotherapy is an independent risk factor for development of acute kidney injury. J BUON, 2018. 23(5): p. 1528-1533.
4. 4. Hakeam, H.A., et al., The incidence of cisplatin nephrotoxicity post hyperthermic intraperitoneal chemotherapy (HIPEC) and cytoreductive surgery. Ren Fail, 2014. 36(10): p. 1486-91.
5. 5. Sin, E.I., et al., Acute kidney injury in ovarian cancer patients undergoing cytoreductive surgery and hyperthermic intra-peritoneal chemotherapy. Int J Hyperthermia, 2017. 33(6): p. 690-695.
6. 6. Cashin, P.H., et al., Pharmacokinetics of cisplatin during hyperthermic intraperitoneal treatment of peritoneal carcinomatosis. Eur J Clin Pharmacol, 2013. 69(3): p. 533-40.
7. 7. Taguchi, T., et al., Cisplatin-associated nephrotoxicity and pathological events. Contrib Nephrol, 2005. 148: p. 107-21.